Cargando…
Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade
Data suggest that for newly approved cancer drugs safety and tolerability are worse than in control arms of registration trials. Less is known about the balance between efficacy and toxicity of drugs studied in unselected phase 3 randomized controlled trials (RCTs) including those not resulting in r...
Autores principales: | Ribnikar, Domen, Goldvaser, Hadar, Veitch, Zachary W., Ocana, Alberto, Templeton, Arnoud J., Šeruga, Boštjan, Amir, Eitan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149406/ https://www.ncbi.nlm.nih.gov/pubmed/34035370 http://dx.doi.org/10.1038/s41598-021-90403-3 |
Ejemplares similares
-
Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
por: Saleh, Ramy R., et al.
Publicado: (2020) -
Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy
por: Ribnikar, Domen, et al.
Publicado: (2023) -
Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019) -
Clinical benefit of cancer drugs approved in Switzerland 2010–2019
por: Adam, Roman, et al.
Publicado: (2022) -
Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014)